Oncolytic virus oHSV2 combined with PD-1/PD-L1 inhibitors exert antitumor activity by mediating CD4 + T and CD8 + T cell infiltration in the lymphoma tumor microenvironment

All roads lead to targeted diffuse large B-cell lymphoma approaches

(2022) Peng-Peng Xu et al.   CANCER CELL

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

(2022) Ming Yi et al.   Molecular Cancer

Overcoming doxorubicin resistance in cancer: siRNA-loaded nanoarchitectures for cancer gene therapy

(2022) Mahshid Deldar Abad Paskeh et al.   LIFE SCIENCES

Oncolytic Viruses: Immunotherapy Drugs for Gastrointestinal Malignant Tumors

(2022) Qingbo Li et al.   Frontiers in Cellular and Infection Microbiology

Doxorubicin Pharmacokinetics and Toxicity in Patients with Aggressive Lymphoma and Hepatic Impairment

(2022) Catherine Lai et al.   Blood Advances

Outcomes in refractory diffuse large B‐cell lymphoma: results from a multicenter real‐world study in China

(2021) Shuo Wang et al.   Cancer Communications

The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives

(2021) Jamal Majidpoor et al.   CLINICAL IMMUNOLOGY

Cytotoxic T lymphocyte‐associated protein 4 antibody aggrandizes antitumor immune response of oncolytic virus M1 via targeting regulatory T cells

(2021) Wenfeng Liu et al.   INTERNATIONAL JOURNAL OF CANCER

Treatment resistance in diffuse large B-cell lymphoma

(2021) Michael Y. He et al.   LEUKEMIA

Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020–2025

(2021) Gena Kanas et al.   LEUKEMIA & LYMPHOMA

Doxorubicin promotes breast cancer cell migration and invasion via DCAF13

(2021) Zhaoran Sun et al.   FEBS Open Bio

Novel Chimeric Immuno-Oncolytic Virus CF33-hNIS-antiPDL1 for the Treatment of Pancreatic Cancer

(2020) Yanghee Woo et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS

Recent advances of oncolytic virus in cancer therapy

(2020) Moumita Mondal et al.   Human Vaccines & Immunotherapeutics

Modeling Oncolytic Viral Therapy, Immune Checkpoint Inhibition, and the Complex Dynamics of Innate and Adaptive Immunity in Glioblastoma Treatment

(2020) Kathleen M. Storey et al.   Frontiers in Physiology

oHSV2 Can Target Murine Colon Carcinoma by Altering the Immune Status of the Tumor Microenvironment and Inducing Antitumor Immunity

(2020) Wen Zhang et al.   Molecular Therapy-Oncolytics

An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses

(2020) Guan Wang et al.   Nature Communications

New molecular and biochemical insights of doxorubicin-induced hepatotoxicity

(2020) Pureti Lakshmi Prasanna et al.   LIFE SCIENCES

Oncolytic Virus Therapy with HSV-1 for Hematological Malignancies

(2020) Ryo Ishino et al.   MOLECULAR THERAPY

Oncolytic Herpes Simplex Virus Type 2 Can Effectively Inhibit Colorectal Cancer Liver Metastasis by Modulating the Immune Status in the Tumor Microenvironment and Inducing Specific Antitumor Immunity

(2020) Wen Zhang et al.   HUMAN GENE THERAPY

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations

(2019) Yongshuai Jiang et al.   Human Vaccines & Immunotherapeutics

Sexual dimorphism of acute doxorubicin-induced nephrotoxicity in C57Bl/6 mice

(2019) Marianne K. O. Grant et al.   PLoS One

Frontline treatment of diffuse large B‐cell lymphoma: Beyond R‐CHOP

(2019) Patrizia Mondello et al.   HEMATOLOGICAL ONCOLOGY

Diffuse Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma

(2019) Jennifer L. Crombie et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Oxidative stress injury in doxorubicin-induced cardiotoxicity

(2019) Mei Songbo et al.   TOXICOLOGY LETTERS

High tumoral PD-L1 expression and low PD-1+ or CD8+ tumor-infiltrating lymphocytes are predictive of a poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system

(2019) Sehui Kim et al.   OncoImmunology

Tumor Microenvironment in Diffuse Large B-Cell Lymphoma: Role and Prognosis

(2019) Alexandra Ioana Cioroianu et al.   Analytical Cellular Pathology

Design and application of oncolytic viruses for cancer immunotherapy

(2019) Erkko Ylösmäki et al.   CURRENT OPINION IN BIOTECHNOLOGY

PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy

(2018) Fatemeh K. Dermani et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Oncolytic virus immunotherapy: future prospects for oncology

(2018) Junaid Raja et al.   Journal for ImmunoTherapy of Cancer

Lymphoma classification update: B-cell non-Hodgkin lymphomas

(2017) Manli Jiang et al.   Expert Review of Hematology

Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma

(2016) Praveen K. Bommareddy et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Increasing role of the cancer chemotherapeutic doxorubicin in cellular metabolism

(2016) Ann-Marie Meredith et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas

(2015) Dohee Kwon et al.   HISTOPATHOLOGY

Oncolytic viruses: a new class of immunotherapy drugs

(2015) Howard L. Kaufman et al.   NATURE REVIEWS DRUG DISCOVERY

Doxorubicin: The Good, the Bad and the Ugly Effect

(2009) Cristina Carvalho et al.   CURRENT MEDICINAL CHEMISTRY